Mostrando entradas con la etiqueta Ethics. Mostrar todas las entradas
Mostrando entradas con la etiqueta Ethics. Mostrar todas las entradas

jueves, 20 de noviembre de 2014

Nanotechnology in biomedicine

Many diseases are caused by alterations in biological processes at the molecular or nanometric level. Mutated genes, misfolded proteins, and infections caused by viruses or bacteria can produce cellular malfunction, translating into serious diseases. These molecules and infectious agents have a nanometric size and may be located in biological systems protected by nanosized barriers such as the nuclear pore with a diameter of 9 nm.

Nanotechnology is defined as the design, characterization, production and application of materials, structures, devices and systems in the nanometric range (1-100 nm).


The application of nanotechnology to medicine is changing the way we look at cancer:


Nanomedicine is aimed to use the characteristics and physical properties of nanomaterials for the diagnosis and treatment of diseases at the molecular level.

In the figure below you can see some of the most frequently used materials in nanomedicine:

Taken from Kim et al. N Engl J Med 2010

Of particular interest is the one-atom thick layer of graphite, called grapheneThe Nobel Prize in Physics 2010 was awarded jointly to the Russian researchers Andre Geim and Konstantin Novoselov "for groundbreaking experiments regarding the two-dimensional material graphene"Graphene is the basic structural element of carbon nanotubes. Below, you can see a video showing how the medical applications of graphene could be in the future:


MEDICAL APPLICATIONS OF NANOTECHNOLOGY
Nanodiagnosis: the diagnosis of some diseases can be improved by using nanoparticles that interact with the molecules related to the disease present in the blood, body fluids or tissues.

Drug release: nanotechnology may be more effective in drug delivery and reaching the target tissue than conventional systems.

Some aspects of the application of nanotechnology in the diagnosis and treatment of cancer can be seen in the following video:



Nanotechnology has also potential in regenerative medicine, particularly in the diagnosis and management of cardiovascular diseases, in the development of prosthesis and in the creation of artificial retina.

Other fields where nanotechnology could have application are: treatment of infectious diseases, nanosurgery and odontology.

In the following video a technique using nanoparticles aimed to reduce the toxicity of radiotherapy and improve the effectivity of the treatment is explained: 

The use of nanoparticules raises novel and important ethical concerns regarding mainly the potential toxic side effects in the body and the potential ecological impact on the environment.




Familiarize yourself with the following concepts:
  • Definition of nanotechnology
  • Principal nanomaterials
  • Applications in biomedicine
  • Advantages and disadvantages of nanotechnology
  • Main ethical concerns

martes, 18 de noviembre de 2014

Stem cells

Stem cells are undifferentiated cells with the ability to divide through mitosis to produce more stem cells (self-renewal) and that can differentiate into specialized cells. 


The relevance of stem cells in biomedical research was reflected in the decision to award Sir John B. Gurdon (Dippenhall, United Kingdom, 1933) and Professor Shinya Yamanaka (Osaka, Japan, 1962) the Nobel Prize of Medicine in 2012 for their findings in this research topic.
 

Stem cells are widely studied, due to their potential therapeutic use and for their inherent interest. As explained during the lesson, stem cell research is now focused on regenerative medicine as well as on the treatment of a wide variety of diseases, including cancer, Parkinson disease, multiple sclerosis, and spinal cord injuries, among others. However, most of the clinical trials using stem cells as therapy are still in early clinical phases. The following video explains what stem cells are and how scientists are harnessing their medical potential:

 


Classification of stem cells according to developmental potentials
  • Totipotent stem cells derive from the fusion of a sperm cell with an egg cell (zygote) or from the first few divisions of the fertilized egg (morula). Totipotent stem cells can give rise to an entire functional organism or to any cell type of the body, including the extraembryonic tissues (i.e. placenta, umbilical cord, amniotic sac).
  • Pluripotent stem cells derive from the inner cell mass of the blastocyst. Pluripotent stem cells can differentiate into nearly all cell types of the three embryonic germ layers (endoderm, mesoderm, ectoderm), but not into an entire functional organism.
  • Multipotent stem cells can develop into more than one cell type, but only those of a closely related family of cells (i.e. multipotent blood stem cells are capable of differentiating into erythrocytes, lymphocytes or platelets).
  • Unipotent stem cells can produce only one cell type, their own, but have the property of self-renewal, which distinguishes them from non-stem cells.


Classification of stem cells according to their origin
  • Embryonic stem cells derive from the embryonic stage of morula (totipotent stem cells) or from the inner cell mass blastocyst (pluripotent stem cells). Due to their high developmental potential, embryonic stem cells can give rise to teratomas, that are tumors containing differentiated elements of all three embryonic germ layers. Isolation of human embryonic stem cells results in the destruction of the fertilized embryo, which raises ethical issues.
  • Adult or somatic stem cells originate from adult tissues and they have the ability to divide or self-renew indefinitely and generate the cell types from the tissue from which they originate. This type of cells are multipotent stem cells.
  • Induced pluripotent stem cells (iPS): Professor Shinya Yamanaka (University of Kyoto, Japan) reprogrammed, for the first time, murine skin fibroblasts into multipotent stem cells that could develop into all cell types of an adult mouse by introducing four factors Oct3/4, Sox2, c-Myc and Klf4. He named the cells induced pluripotent stem cells (iPS) and these results were published in the prestigious Cell journal in 2006. In the present video, you can see the methods used to obtain iPS cells:
 


You will have to know the:
  • Classification and characteristics of stem cells according to their developmental potential (totipotent, pluripotent, multipotent and unipotent stem cells).
  • Classification and characteristics of stem cells according to their origin (embryonic, adult and inducible pluripotent stem cells).
  • Genes implicated in the induction of iPS cells.

jueves, 16 de octubre de 2014

Pharmaceutical R+D

What is a drug?

In Pharmacology, a drug is a natural or synthetic substance able to produce biological or functional effect in a living organism. A medication is a drug used for the treatment, cure, prevention, or diagnosis of a disease as well as in some condition to enhance physical or mental well-being.

Preclinical phase

After the drug discovery, its biological activity is analysed in computational models, cell cultures or animals (from less to more sensitive according to their phylogenetic scale) following the 3 R's principle of Russell and Burch. The protocols must be submitted and approved by the Ethical Committee of Experimental Animal Research of the university or research centre where the research is going to be carried out. 

Preclinical studies are also required to determine the efficacy of the medicament via the pharmacokinetic (the response of the organism to the drug) and pharmacodynamic (how the drug acts in the organism) analyses. In addition, the security of the drug needs to be evaluated by toxicological studies after chronic and acute exposure.  An improper testing of the efficacy or security of the drugs can cause serious health problems in the clinical stage, as happened in the middle of the XX century with Thalidomide, a drug prescribed as a sedative and antiemetic for morning sickness. Thousands of pregnant women took Thalidomide to relieve their symptoms. In the late 50's and early 60's reports of children born with deformities such as phocomelia (rare congenital disorder involving malformations of the limbs, see picture in the right) as a consequence of Thalidomide use saw the light. The effects of Thalidomide raised the issue of safety of pharmaceutical drugs with testing and approval of toxins becaming more important.

After preclinical testing, the drug can progress to the clinical phase following the positive evaluation of the National (AEMPS: Agencia Española de Medicamentos y Productos Sanitarios in Spain), European (EMA: European Medicines Agency) or American (FDA: Food and Drug Administration) authorities.

Clinical phase 

The clinical phase includes a serial of tests to ensure the efficacy and security in humans as well as to generate data of the adverse drug reactions or adverse effects with other treatments. All the investigations must conform to the Declaration of Helsinki and the protocols must be submitted and approved by the Ethical Committee of Clinical Research. The clinical developmental phases are:
  • Phase I: the drug is administered, for the first time, to 20-100 healthy individuals in order to evaluate the safety of the dosage and how the drug should be given. Usually this stage lasts from 6 to 12 months.
  • Phase II:  the biological activity and the optimal dosage of the drug is tested in 100-200 patients and healthy individuals involved in blind clinical trials. Information about the drug's safety, side effects and potential risks are also collected. This phase of the clinical trial lasts between 1-2 years.
  • Phase III trials enroll a large number of individuals (1,000-3,000 patients) in order to compare the efficacy of the new drug with other existing medicaments in a double-blind, randomized study. Additional information about the safety and side effects of the drug is gathered during a period of 2-3 years. Once the drug has been proven succesful in the Phase III clinical trial, the researchers can submit an application to AEMPS, EMA or FDA approval. If data from the clinical trial meet the AEMPS's, EMA's or FDA's standards of safety and efficacy, the drug is approved for a specific use.
  • Phase IV or post-marketing surveillance: the safety surveillance is designed to detect any rare or long-term adverse effects over a large population. Harmful effects can result in a drug being withdrawn or restricted to certain uses. A recent example include rofecobix (Vioxx), a nonsteroidal antiinflammatory drug used for the treatment of osteoarthritis, acute pain and dysmenorrhoea, that was withdrawn from the market because it caused serious secondary cardiovascular effects.
The entire process of a drug from the lab to this point may take approximately 12-18 years. In the following video, you can see a summary of the 4 stages of the clinical phase:





You will have to know all the phases of the pharmaceutical R&D process as well as their main characteristics:
 



martes, 14 de octubre de 2014

Scientific Writing



Today we have addressed the topic of how to present data in written form, focusing mainly on writing papers for biomedical journals. Why is writing important in science? Scientists need to communicate their findings and this is usually achieved via publishing their work in scientific journals. Thus, a critical aspect of the scientific process is to share your information and experience with the scientific community. Reporting your new results in biomedical journals is a quick way to disseminate the information to the specialized community contributing to increase the knowledge within a discipline as well as to help others interpret their own results.



Types of articles

We have mentioned
in class the different types of articles and their main characteristics. While most articles published are original research papers, there are also reviews, editorials, commentaries, perspectives, case reports or letters to the editor, among others.



Fundamental style considerations

In the
International Committee of Medical Journal Editors - ICMJE) you can find the Uniform Requirements for Manuscripts. Most biomedical journals have their own format, structure and writing styles. Therefore, it is important that you are familiar with the Instructions for Authors of the specific journal you aim to submit your manuscript.

Your text should conform to the conventions of standard written English (sentence form, grammar, spelling, etc.). Structure your sentences carefully using the basic division into subject, verb, and complement. In addition, the structure of the sentence will convey emphasis, draw attention to the most important part at the same time as help readers to interpret your meaning correctly. Moreover, you should structure your sentences and paragraphs to flow, conferring your article cohesion and coherence.
 
Your ideas will have little impact, no matter how good the research is, if they are not communicated effectively!

Keep in mind that scientific terminology has precise meaning. Thus, be certain you select your words correctly and adequately; write clearly and concisely. Writing and thinking are very closely linked, "fuzzy writing reflects fuzzy thinking". When people have difficulties in translating their ideas into words, it generally reflects that they may not be fully aware of what they want to transmit.
  • Adapt to the special requirements of your selected audience, journal and type of article.
  • Be precise and accurate: Scientific terminology carries specific meaning; learn to use it appropriately and consistently. In fact, it takes a deeper understanding to explain a complex topic simply and succinctly. 
  • Be clear and concise: Write briefly and to the point. Say what you mean simply and clearly avoiding embellishment with unnecessary words or phrases. Brevity is very important. Do not use colloquial speech or slang; do not use contractions like for example "don't" or "isn't".
"Brevity is the soul of wit" (W. Shakespeare)

Considerations for the preparation of a research article

One of the initial considerations is to choose the appropriate readership for your article. Usually you will be writing to your peers. Knowing your audience will help you to decide what information to include. Obviously, you write a very different article for a highly specialized, technical, disciplinary journal as opposed to a more general publication that covers a broad range of disciplines.  Another relevant aspect to take into account is the impact factor of the journal. 

The first step in the process of writing is to order and organize the information you wish to present. Another critical point when preparing your first draft is to decide the authors and their specific order. The choice of a good title is also extraordinarily important; it should be informative at the same time as attractive and objective. Some people work well from an outline, others do not. Whatever system you follow, be aware that scientific writing requires special attention to order and organization. Because the paper will be divided into sections, you need to know what information will go into each.
The following video very nicely summarizes the main sections of an article and their content.




  • You need to know the different types of articles (original research papers, reviews, editorials, commentaries, perspectives, case reports and letters to the editor, among others) together with their main characteristics and usefulness.

  • In addition, you have to be familiarized with the main sections of a research article, how to structure and develop them in order to communicate effectively. 


jueves, 25 de septiembre de 2014

Scientific Rigor

Any scientific study should follow the steps of the scientific method. Experimental data should be collected methodically, systematically, randomly, ethically and with minimum bias. The scientific community does research following a series of principles including integrity, objectivity and honesty, which constitute what is known as scientific rigor. Nowadays, a scientific finding is published after being evaluated by other researchers, in what is known as peer review. However, due to work and academic pressure researchers sometimes proceed inappropriately in what is known as scientific misconduct. There are several actions that can be considered scientific misconduct, among which are the falsification or fabrication of data, lack of ethics or plagiarism. The latter is described in the video shown below.




There are different methods to detect this kind of behaviour. To this end, the scientific community has created entities like the Office of Research Integrity, which ensures the integrity of the scientific production in the United States, trying to detect cases of scientific misconduct.







jueves, 18 de septiembre de 2014

Animal research ethics

Experimental animals are key elements for biomedical research, since they are used to develop strategies for the prevention and treatment of several transmissible and non-transmissible diseases, such as the vaccines for rabies, smallpox, tetanus, diphtheria, pertussis or poliomyelitis, as well as the antibiotics or insulin treatment for diabetics.


Nowadays, there are also alternatives to the use of experimental animals. However, some type of experiments (i.e. research of certain pathologies and drugs) do not have alternative to animal testing, and submission and approval of the Ethical Committee for Animal Experimentation of the University or the Research Centre were the research project is going to be developed is required. The use of experimental animals must conform to the European Guidelines for the Care and Use of Laboratory Animals (Directive 2010/63/EU) as well as to the national (Real Decreto 53/2013and regional (Orden Foral del 5 de Agosto de 1991 in Navarra) legal framework.

What are the 3 R's?

In 1959, the zoologist William Moy Stratton Russell (1925-2006) and the microbiologist Rex Leonard Burch (1926-1996) wrote that scientific excellence and humane use of laboratory animals are inextricably linked. In the book “The Principles of Humane Experimental Technique”, they described “The 3 R’s” (Reduction, Refinement and Replacement), which are the ethical guidelines for animal use in life sciences. 

Russell and Burch were honoured guests in several major meetings regarding alternatives for the use of experimental animals. The brilliant Russell with a generous and cheerful disposition and the propensity to break out in a song, explained the benefits of the 3 R's in the 2nd World Congress on Alternatives and Animal Use in the Life Sciences (Utrecht, The Netherlands, 1996) with a song, as you can observe in this video.

The 3 R's principle of Russell and Burch includes:
  • Reduction: the number of animals should be the minimum necessary to test the experimental hypothesis and give statistically reliable results. In order to calculate an appropriate sample size, a priori statistic criteria should be used. The validation of alternative methods to the use of animals is also key to reduce the number of animals.
  • Refinement: the procedures should be selected to eliminate or minimize the pain and distress or enhance the animal welfare. Much pain and distress can be reduced or eliminated by using analgesia, anaesthesia and non-invasive methods. Researchers can enhance the well-being of the experimental animals by using environmental enrichment techniques, such as proper handling, appropriately sized cages, or group housing of social species.
  • Replacement alternatives include methods using less sensitive species (i.e. microorganisms, plants or invertebrates) or completely avoid the use of experimental animals, such as: i) mathematical and computer models; ii) in vitro studies with organs, tissues or cells in culture; and iii) human studies by using volunteers, surveys and epidemiology.       


CROSSWORD: complete the following crossword using one letter in each cell.
ACROSS:
  1. The use of non-invasive procedures belongs to this "R" of the 3 R's principle.
  2. A physician needs this academic degree and, at least, 10 years of experience in the use of experimental animals to obtain the C category for animal research (from right to left).
  3. Ethically unacceptable end-point.
  4. A method of refinement to achieve the absence of sense of pain while remaining conscious.
  5. The "R" corresponding to the use of the minimum number of animals to achieve statistically reliable results.
  6. Point at which the experiment is complete (from right to left).
  7. Russell and _______ defined the 3 R's principle (from right to left).
  8. Sheeps are _______ animals that require to be housed in social groups.
  9. Term that refers to repetitive behaviours in captive animals, particularly those given an inadequate mental stimulation.
DOWN:

  1. The use of less sensitive species belongs to this "R" of the 3 R's principle.
  2. A period of isolation of the experimental animals arriving from abroad to prevent the spread of diseases and allow the animals to adapt to their new environment (from bottom to top).
  3. _____ studies are preliminary studies used to evaluate the feasibility, time, cost or adverse effects in an attempt to predict an appropriate sample size and improve the methodology upon the final study.
  4. The ________ mouse is an animal model of immune deficiency due to a genetic mutation that causes a deteriorated or absent thymus and requires aseptic housing conditions (i.e. positive air pressure cages).  
  5. The use of ___________ is required to calculate an appropriate sample size.
  6. Two words: building where the experimental animals are housed.
  7. As researchers, if we must conform the Directive 2010/63/EU for the care and use of laboratory animals, we live in ________.
  8. Experimental animals usually show identical _________ with the same phenotype to ensure reproducibility under the same experimental conditions.
  9. The ethical guidelines for the use of experimental animals are resumed in the _____ principle (from bottom to top).














 



ANSWERS TO THE CROSSWORD:



miércoles, 17 de septiembre de 2014

Practical Session 1 - Group 1

We have used the first part of the session to explain in great detail what we expect from you in the team work (which is mandatory) as well in the individual essay (which is optional) of our subject. Subsequently, we have shown a film ideally suited to discuss topics related to research ranging from the relevance of the scientific method to the intricacies of ethics.

“Something the Lord Made”

The movie “Something the Lord Made” is based on the verifiable facts of the clinical and experimental work that led to the first-ever surgical intervention with therapeutical purposes on a child suffering from Tetralogy of Fallot (to see the main features of Fallot's tetralogy, please, refer to the Keys of the Practical Session in the post corresponding to Group 2).
The following video outlines in a schematic way the main alterations of this pathology and how they are being surgically repaired nowadays. 



For those of you interested in learning more about how the operation is performed at present go to the explanations and video provided in the link corresponding to Practical Session 1 - Group 3 under the subheading surgical treatment of Tetralogy of Fallot).

Blalock and Taussig published in 1945 the positive results of their first 3 interventions on children with Tetralogy of Fallot in JAMA, one of the most prestigious medical journals.

In spite of the key contributions of Vivien Thomas in the research leading to the development of the surgical technique (subsequently termed the “Blalock-Taussig shunt”), his name does not appear among the authors of the original article. This fact was emphasized some years ago in a comment published in the same journal referring to the Blalock, Taussig & Thomas collaboration as an excellent example of translational research and the impact it exerted on the development of medicine

What do the human heart and a super tanker have in common?

Facts:

Your heart beats about 100,000 times in one day and about 35 million times in a year. During an average lifetime, the human heart will beat more than 2.5 billion times.

Your body has about 5.6 liters of blood, which circulates through the body 3 times every minute. In one day, the blood travels a total of 19,000 km (12,000 miles) — that's around 4 times the distance across the US from coast to coast.

The heart pumps about 1 million barrels of blood during an average lifetime—that's enough to fill more than a couple of modern super tankers. 
 

martes, 16 de septiembre de 2014

Biomedical research ethics


Biomedical research is needed for the development of medicine. It provides the scientific evidence to improve health care by providing knowledge and information on the usefulness and effectiveness of diagnostic, therapeutic and preventive procedures. Moreover, biomedical research contributes to increase our understanding of the etiology, pathophysiology and risk factors of diseases.

In other words, biomedical research is the careful, meticulous, systematic, diligent inquiry or examination of current knowledge, undertaken to establish facts or principles. Researchers strive to better understand the causes of disease, expand knowledge to discover better ways to prevent ill health, and to develop beneficial medications, and procedures to treat and cure diseases and conditions that cause illness and death. For all these reasons biomedical research should be considered a moral obligation for all physicians and health professionals (37% of you answered correctly via the clickers).

Ethical biomedical research encompasses not only the attainment of moral aims or purposes but also the application of morally acceptable means to obtain them. Therefore, scientific rigor is a necessary condition but not a sufficient one; not all what is scientifically feasible may be acceptable from an ethical standpoint.

Ethics is a set of moral obligations that define what is right and wrong in our practices and decisions. Scientists have long maintained an informal system of ethics and guidelines for conducting research, but documented ethical guidelines did not develop until the mid-twentieth century, after a series of well-publicized ethical breaches and war crimes.
 
During World War II, Nazi scientists launched, among others, a series of studies designed to test the limits of human exposure to the elements with the final aim of better preparing German soldiers. For instance, some experiments addressed the effects of hypothermia in humans. During these experiments, concentration camp prisoners were forced to sit in ice water or were left naked outdoors in freezing temperatures for hours. Numerous victims were left to freeze to death while others were eventually re-warmed with blankets or warm water, or underwent experimental rewarming attempts that left them with permanent injuries. War crimes during World War II led to the Nüremberg Code (1947).

In 1932 the U.S. Public Health Service started the “Tuskegee Study”, an experiment on black men in the late stages of syphilis. These men, for the most part illiterate sharecroppers from one of the poorest counties in Alabama, were never told what disease they were suffering from or of its seriousness. They were only informed to be treated for “bad blood”, and their doctors had no intention of curing them of syphilis at all. The experiment was aimed to collect data from autopsies of the participating men, and they were thus deliberately left to degenerate under the ravages of tertiary syphilis, which can include tumours, heart disease, paralysis, blindness, insanity, and death.

The following video summarizes the atrocities of the “Tuskegee Syphilis Study” and has served us to reflect on the ethical implications and consequences.



Infamous cases of fraud and misconduct highlight the need for a system of ethics to ensure proper behaviour and reliable research in science. As a result of the Tuskegee Syphilis Study (1932-1972), the U.S. Congress passed the National Research Act in 1974. The Act created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research to oversee and regulate the use of human experimentation and defined the requirements for Institutional Review Boards. To assure that research is conducted in accordance with basic ethical principles, the Commission considered:
  1. the boundaries between biomedical and behavioral research and the accepted and routine practice of medicine,
  2. the role of assessment of risk-benefit criteria in the determination of the appropriateness of research involving human subjects,
  3. the establishment of appropriate guidelines for the selection of human subjects for participation in such research, and
  4. the nature and definition of informed consent in various research settings.
The Belmont Report

The work of the National Commission led to The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research which was presented in 1978 and published in 1979 that states that “persons are treated in an ethical manner not only by respecting their decisions and protecting them from harm, but also by making efforts to secure their well being”. The Belmont Report summarized and defined the basic ethical principles of respect, justice and beneficence, thereby representing the origins of modern research ethics.
 
Basic Ethical Principles

1. Principle of autonomy: recognizes the rights of individuals to self-determination. The respect for persons incorporates at least 2 ethical convictions: first, that individuals should be treated as autonomous agents, and second, that persons with diminished autonomy are entitled to protection.
This principle of respect for persons thus translates into two separate moral requirements:
(i) to acknowledge autonomy and
(ii) to protect those with diminished autonomy.
To respect autonomy is to give weight to the person’s autonomous considered opinions and choices while refraining from obstructing their actions unless they are clearly detrimental to others. Withholding information necessary to make a considered judgment, when there are no compelling reasons to do so represents a lack of respect.

However, it has to be highlighted that not every human being is capable of self-determination. The capacity for self-determination matures during an individual's life, while some individuals lose this capacity wholly or in part as a consequence of illness, mental disability, or circumstances that severely restrict liberty. Respect for the immature and the incapacitated requires protecting them as they mature or while they are incapacitated. Respect for persons demands that subjects enter into the research voluntarily and with an adequate information (informed consent).

2) Principle of justice: refers to the ethical obligation of fairness and equality in health resources and treatment. The conception of justice is especially relevant to protect vulnerable groups. In this regard, the selection of research subjects needs to be scrutinized in order not to be discriminatory. It should be determined whether some classes (e.g., welfare patients, particular racial and ethnic minorities, or persons confined to institutions) are being systematically selected simply because of their easy availability, their compromised position, or their manipulability, rather than for reasons directly related to the research condition being studied. Furthermore, justice demands that when research leads to the development of therapeutic devices and procedures, these not provide advantages only to those who can afford them as well as that such research should not unduly involve persons from groups unlikely to be among the beneficiaries of subsequent applications of the research.
3) Principle of beneficence: means the obligation to act in the best interest of patients maximizing possible benefits and minimizing possible harms. Individuals are treated in an ethical manner not only by respecting their decisions, but also by making efforts to secure their well-being. This principle establishes the need to carefully evaluate the risk-benefit relation; learning what will in fact be beneficial may require exposing persons to risk. The imperative posed by this principle is to decide when it is justifiable to seek certain benefits despite the risks involved, and when the benefits should be foregone because of the risks. Moreover, this principle implies the professional competence of the researchers involved to warrant maximization of benefits and the reduction of risk that might occur from the investigation.

The concept of non-maleficence considers that it is more important not to harm your patient, than to do them good; this is embodied by the Latin expression “primum non nocere”, "first, do no harm".

The Declaration of Helsinki

The Declaration of Helsinki represents one of the most relevant documents in the history of research ethics as the first significant effort of the medical community to regulate research itself. With the primary purpose to set international ethical principles for research involving human participants the World Medical Association (WMA), the Declaration of Helsinki was originally enacted in 1964 and forms the basis of most subsequent documents. It has undergone various revisions (the most recent at the General Assembly in October 2013) since its first promulgation. Given that 2014 marked the 50th anniversary of the Declaration of Helsinki, the WMA developed its eighth version of the Declaration updating and revising the 2008 version with the core aim of the working party to preserve the unique character and status of the document. The first draft was out for public consultation until June 15th, 2013 while the final revised and updated version was published in JAMA in November 2013. Major changes with respect to the 2008 version were carried out regarding both its structure and content. Noteworthy, the duty of physicians expands not only to promote and safeguard health but also well-being. The articles pertaining to vulnerable populations have also been changed to better capture several important ethical principles. Although the WMA has been congratulated for the work performed and the transparency of the process, it was agreed that the declaration has not undergone radical change representing “an evolution rather than a revolution”. Additional distinctive aspects contemplated in the 2013 version include appropriate access of underrepresented groups to participation in medical research, the need for compensation for study participants who are inadvertently harmed, and attempts to further clarify the role of placebos, the need to register every study involving human subjects in a publicly accesible database before recruitment of the first subject, provision for post-trial arrangements in advance of study start, and the ethical obligation to publish and disseminate the study results, even if they are negative or inconclusive.





  • Understand and remember the basic ethical principles of respect, justice and beneficence derived from the Belmont Report.
  • Study in detail the 2013 revision of the Declaration of Helsinki together with the changes introduced as compared to the 2008  version (pdfs available at ADI).
  • Learn the characteristics and content of the written informed consent.